Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma

Gencay Hatiboglu,Markus Hohenfellner,Aysenur Arslan,Boris Hadaschik,Dogu Teber,Jan Philipp Radtke,Peter Hallscheidt,Yanis Tolstov,Wilfried Roth,Carsten Grüllich,Johannes Huesing,Stefan Duensing,Sascha Pahernik

Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma

2017

Gencay Hatiboglu
Markus Hohenfellner
Aysenur Arslan
Boris Hadaschik
Dogu Teber
Jan Philipp Radtke
Peter Hallscheidt
Yanis Tolstov
Wilfried Roth
Carsten Grüllich
Johannes Huesing
Stefan Duensing
Sascha Pahernik

Objectives To evaluate the safety and feasibility of sorafenib prior to surgery for downsizing tumors in patients with non-metastatic cT1-3 renal tumors together with a characterization of functional intratumoral heterogeneity (ITH).

Keywords:

Surgery
General surgery
Sorafenib
Renal cell carcinoma
Medicine
Cardiac surgery
in patient
non metastatic
Abdominal surgery
Cardiothoracic surgery
Vascular surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations